Literature DB >> 10471066

UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations.

J W Lampe1, J Bigler, N K Horner, J D Potter.   

Abstract

Polymorphisms that alter UDP-glucuronosyltransferase (UGT) activities have been identified. Mutations in the promoter of the UGT1A1 gene (UGT1A1*28), resulting in 5, 7 or 8, instead of 6 thymine-adenine (TA) repeats, alter bilirubin conjugation. Two missense mutations on one allele of UGT1A6 (UGT1A6*2) result in T181A and R184S amino acid substitutions and reduced activity against phenolics, such as 4-nitrophenol, 4-hydroxycoumarin and butylated hydroxy anisole. We determined the frequency of these polymorphisms in 245 healthy men and women, aged 20-40 years and examined the relationship between TA repeat number and serum bilirubin concentrations in a subset of 24 Asians and 169 Caucasians. The frequencies of the UGT1A1*28 genotypes were 0.537, 0.348, 0.098, 0.008 and 0.008 for promoter TA repeats 6/6, 6/7, 7/7, 5/6 and 6/8, respectively. Both allele and genotype frequencies varied by race (P < 0.02), with 11% of the Caucasians and none of the Asians having the 7/7 genotype. Within both ethnic groups, serum bilirubin increased with increased numbers of UGT1A1 promoter TA repeats (P = 0.0001). However, a strong ethnic group-by-UGT1A1 genotype interaction suggests that additional ethnic differences in bilirubin metabolism contribute to observed bilirubin concentrations. Genotype frequencies for UGT1A6*2 were 0.478, 0.392, 0.029, 0.090, 0.012 for wild-type (wt)/wt, wt/T181A + R184S, wt/R184S, T181A + R184S/T181A + R184S and T181A + R184S/R184S, respectively. The co-occurrence of polymorphisms in UGT1A1 and UGT1A6 differed from that expected (P < 0.0001): individuals homozygous wild-type for UGT1A1 and UGT1A6 were observed at twice the expected frequency; individuals homozygous variant for both genes were ten-fold more frequent and individuals homozygous wild-type for one gene and homozygous variant for the other were ten-fold less frequent than expected. Overall, 8% were homozygous variant for both UGT1 polymorphisms and 43% had at least one variant allele for both UGT1A1*28 and UGT1A6*2. These highly prevalent polymorphisms, which result in modified expression and activity of UGTs, may influence susceptibility to cancers associated with altered metabolism of endogenous and xenobiotic compounds.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10471066     DOI: 10.1097/00008571-199906000-00009

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  50 in total

1.  Pharmacogenetics: implementing personalized medicine.

Authors:  Enrico Mini; Stefania Nobili
Journal:  Clin Cases Miner Bone Metab       Date:  2009-01

2.  Associations between polymorphisms in glucuronidation and sulfation enzymes and sex steroid concentrations in premenopausal women in the United States.

Authors:  Mellissa Yong; Stephen M Schwartz; Charlotte Atkinson; Karen W Makar; Sushma S Thomas; Frank Z Stanczyk; Kim C Westerlind; Katherine M Newton; Victoria L Holt; Wendy M Leisenring; Johanna W Lampe
Journal:  J Steroid Biochem Mol Biol       Date:  2010-12-28       Impact factor: 4.292

3.  Gilbert's syndrome: High frequency of the (TA)7 TAA allele in India and its interaction with a novel CAT insertion in promoter of the gene for bilirubin UDP-glucuronosyltransferase 1 gene.

Authors:  Shabana Farheen; Sanghamitra Sengupta; Amal Santra; Suparna Pal; Gopal Krishna Dhali; Meenakshi Chakravorty; Partha P Majumder; Abhijit Chowdhury
Journal:  World J Gastroenterol       Date:  2006-04-14       Impact factor: 5.742

Review 4.  A review of gene-drug interactions for nonsteroidal anti-inflammatory drug use in preventing colorectal neoplasia.

Authors:  J T Cross; E M Poole; C M Ulrich
Journal:  Pharmacogenomics J       Date:  2008-01-15       Impact factor: 3.550

5.  Polymorphisms in genes encoding acetylsalicylic acid metabolizing enzymes are unrelated to upper gastrointestinal health in cardiovascular patients on acetylsalicylic acid.

Authors:  Martijn G H van Oijen; Sylvie Huybers; Wilbert H M Peters; Joost P H Drenth; Robert J F Laheij; Freek W A Verheugt; Jan B M J Jansen
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

6.  N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy.

Authors:  Jennifer A Crozier; Pooja P Advani; Betsy LaPlant; Timothy Hobday; Anthony J Jaslowski; Alvaro Moreno-Aspitia; Edith A Perez
Journal:  Clin Breast Cancer       Date:  2015-08-19       Impact factor: 3.225

7.  C-reactive protein genotypes and haplotypes, polymorphisms in NSAID-metabolizing enzymes, and risk of colorectal polyps.

Authors:  Elizabeth M Poole; Jeannette Bigler; John Whitton; Justin G Sibert; John D Potter; Cornelia M Ulrich
Journal:  Pharmacogenet Genomics       Date:  2009-02       Impact factor: 2.089

8.  Citrus fruit intake is associated with lower serum bilirubin concentration among women with the UGT1A1*28 polymorphism.

Authors:  Misty R Saracino; Jeannette Bigler; Yvonne Schwarz; Jyh-Lurn Chang; Shiuying Li; Lin Li; Emily White; John D Potter; Johanna W Lampe
Journal:  J Nutr       Date:  2009-01-13       Impact factor: 4.798

9.  The preventive factors for aspirin-induced peptic ulcer: aspirin ulcer and corpus atrophy.

Authors:  Akiko Shiotani; Takashi Sakakibara; Yoshiyuki Yamanaka; Ryuji Nishi; Hiroshi Imamura; Minoru Fujita; Ken-ichi Tarumi; Tomoari Kamada; Jiro Hata; Ken Haruma
Journal:  J Gastroenterol       Date:  2009-05-16       Impact factor: 7.527

10.  Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers.

Authors:  Y K Pithavala; M Tortorici; M Toh; M Garrett; B Hee; U Kuruganti; G Ni; K J Klamerus
Journal:  Cancer Chemother Pharmacol       Date:  2009-07-15       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.